Pandemic influenza: Vaccine manufacturers are now actively producing H1N1 pandemic specific vaccine. The US ACIP committee has recently published recommendations regarding initial target groups for vaccination. Prioritization will be especially relevant if initial supplies are limited.
Using currently available information regarding the expected profile, predicted allocation of H1N1 specific vaccine and
predictions of pandemic severity, VacZine Analytics has modelled theoretical global vaccine demand.
The provided model and presentation also give indications of potential cumulative revenue (for vaccine
manufacturers) using adjustable inputs of vaccine pricing, penetration and number of doses per course.
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW.
For UK orders VAT will be added at 15.0%.
Please review the TERMS and CONDITIONS of purchase.
